2002 Fiscal Year Final Research Report Summary
DEVELOPMENT AND CLINICAL APPLICATION OF VECTOR INJECTION DEVICE FOR GENE THERAPY OF SOLID TUMOR
| Project/Area Number |
13557134
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 展開研究 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
NASU Yasutomo Okayama University, Graduate School of Medicine and Dentistry, Assistant Professor, 医学部附属病院, 講師 (20237572)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ARATA Ryoji Okayama University Hospital, Lecturer, 医学部附属病院, 助手 (00314675)
TSUSHIMA Tomoyasu Okayama University, Graduate School of Medicine and Dentistry, Associate Professor, 大学院・医歯学総合研究科, 助教授 (20135990)
KUMON Hiromi Okayama University, Graduate School of Medicine and Dentistry, Professor, 大学院・医歯学総合研究科, 教授 (30144760)
|
|---|
| Project Period (FY) |
2001 – 2002
|
| Keywords | gene therapy / solid tumor / prostate cancer |
|---|
| Research Abstract |
We have innovated a new device, for vector injection for gene therapy of solid tumor and applied for patent. In this study we actually constructed this machine and preliminary checked its safety, condition and adjusted optimal condition for actual injection. In our series prostate was regarded as a target organ.
1)Experiment using free meat block to determine optimal injection condition
By injecting a dye into free meat block, optimal condition of injection was analyzed. As a result, injection speed at 0.1ml/second was thought to be optimal.
2)Improvement of the device
For the improvement of the each part, a simulation was repeated. Major improvement is a formation of foot switch so as the operator can handle the device with his eye kept of the ultrasound screen. We made injection on speed and volume changeable so as we can change the injection condition depending on the tumor volume.
3)Actual injection to the patinets
We have a prostate cancer gene therapy protocol for the patients of local recurrence after hormonal therapy without evidence of metastasis. This protocol is approved by IRE and government. A replication-deficient adenovirus (ADV) containing the herpes simplex virus thymidine kinase gene (HSV-tk) is injected directly into the prostate under ultrasound guidance, followed by intravenous administration of the prodrug ganciclovir (GCV) for 14 days.. Seven cases were injected using this device and injections wete performed precisely and consistently. It is concluded that this device is reliable and useful for vector injection and applicable for the other cancer.
|
Research Products
(12 results)
